



Marco de Morpurgo

Partner

GLOBAL CO-CHAIR, LIFE SCIENCES SECTOR

marco.demorpurgo@dlapiper.com

Roma

T: +39 06 68 880 1

F: +39 06 68 880 201

Marco è Partner nel dipartimento di Intellectual Property & Technology e lavora presso l'ufficio di Roma.

La sua pratica si concentra sulla regolamentazione del settore Life Sciences: assiste aziende che operano nell'Unione europea a muoversi nel complesso quadro regolatorio che governa il settore, prestando assistenza con riferimento ad aspetti strategici e di compliance. Ha consolidata esperienza in merito alla normativa europea e nazionale.

Ha una vasta esperienza nell'assistere clienti nazionali e internazionali nella gestione delle divergenze regolatorie all'interno dell'UE e a livello globale.

Si occupa della regolamentazione di prodotti farmaceutici, biotecnologie, dispositivi medici, alimenti, bevande ed altri prodotti inerenti la salute. Presta consulenza strategica relativamente a una vasta gamma di tematiche regolatorie, inter alia sperimentazioni cliniche, autorizzazioni di prodotti, accesso al mercato, promozione e pubblicità, obblighi post-commercializzazione, nonché normativa anti-corruzione e regole etiche e comportamentali specifiche del settore. Fornisce inoltre supporto regolatorio nelle transazioni Life Sciences e nei contenziosi di proprietà intellettuale.

SERVIZI CORRELATI

- Intellectual Property and Technology

SETTORI CORRELATI

- Life sciences

LINGUE

Italiano Inglese
Francese Spagnolo

LINGUE

- Italiano
- Inglese
- Francese
- Spagnolo

CREDENZIALI

Qualifiche professionali

- Avvocato iscritto all'Ordine degli Avvocati di Roma

- Avocat admitted to the Paris Bar
- Abogado registered with Ilustre Colegio de Abogados de Madrid
- Attorney-at-law iscritto al Supreme Court of New York

Esperienze progressse

- Prima di unirsi a DLA Piper, Marco ha collaborato con primari studi interazionali in Bruxelles, Londra e Parigi.

Formazione

- Università degli Studi di Milano, Ph.D., Comparative Law
- Harvard Law School, LL.M.
- IUC Turin, M.Sc., Comparative Law, Economics & Finance
- Università di Trieste, Laurea in Giurisprudenza

TENERSI INFORMATI

Pubblicazioni

Italian Medicines Agency tackles challenges related to clinical trial management during COVID-19 emergency

20 March 2020

In the recent UK Budget, and subsequent announcements, several initiatives have been introduced to support businesses in response to coronavirus COVID-19, but as yet there are no generally applicable leniencies on when tax has to be paid or returns filed. Read to find out more.

Italian DLA Piper Intellectual Property & Technology Legal Predictions for 2020

28 February 2020

DLA Piper Italian Intellectual Property & Technology practice group has published its Legal Predictions for 2019. These take a look back at what happened during 2019 and illustrate the key changes that are expected in 2020.

New transparency obligations for medical device companies in Italy

20 January 2020

On 1 January 2021, important transparency obligations provided for in the Code of Ethics of Confindustria Dispositivi Medici (the Italian medical device industry association) will become applicable.

Top 3 Predictions for Life Sciences in 2019

22 JAN 2019

The Life Sciences industry operates in one of the fastest and most innovation-driven environments. 2018 has witnessed significant developments in technology and therapeutic practices. A number of new cell and gene therapies – including the first two CAR-T therapies for cancer – received EU approval, and both disruptive and ‘new mainstream’ technologies (such as AI) made significant steps forward into the sector.

- EU SPC Manufacturing Waiver Becomes Effective: What Can Industry Expect?, European Pharmaceutical Law Review, Volume 3, Issue 3 (2019)
- The Sun Also Rises in Italy: New Statutory Transparency Requirements Expected under the Proposed Italian Sunshine Act, European Pharmaceutical Law Review, Volume 2, Issue 4 (2018)
- Italy Reforms Clinical Trial Rules, European Pharmaceutical Law Review, Volume 2, Issue 1 (2018)

NEWS

DLA Piper launches global cannabis practice

21 February 2020

DLA Piper has launched a dedicated global cannabis practice that will sit as a sub-group under its Life Sciences sector. The decision to formalise the firm's offering follows the completion of a significant number of global deals in the sector that have amounted to over USD8 billion to date, as well as a number of large cannabis regulatory advisory mandates.

DLA Piper hires Life Sciences regulatory specialist in Rome

9 OCT 2018

DLA Piper has appointed Marco de Morpurgo as partner to its Intellectual Property and Technology (IPT) practice group in Rome.
